A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

被引：1
|
作者：
Lu, S. [1 ]
Zhou, J. [2 ]
Niu, X. [3 ]
Chen, M. [4 ]
Hua, Y. [4 ]
Su, W. [4 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Shanghai, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Hutchison Medipharma, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Fruquintinib; non-small cell lung cancer; gefitinib;
D O I：
10.1016/j.jtho.2017.09.301
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
JCES 01.12
引用
收藏
页码：S1735 / S1735
页数：1
相关论文
共 50 条
  • [21] Gefitinib plus celecoxilb in chernotherapy-naive patients with stage IIIB/IV non-small cell lung cancer - A phase II study from the Hoosier Oncology Group
    Agarwala, Anuj
    Fisher, William
    Bruetman, Daniel
    McClean, John
    Taber, David
    Titzer, Michael
    Juliar, Beth
    Yu, Menggang
    Breen, Tim
    Einhorn, Lawrence H.
    Hanna, Nasser
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 374 - 379
  • [22] A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC)
    Ginopoulos, P
    Mastronikolis, NS
    Giannios, J
    Karana, A
    Siabi, V
    Karvelas, F
    Rathossis, S
    Apostolopoulos, N
    Mastorakou, A
    LUNG CANCER, 1999, 23 (01) : 31 - 37
  • [23] Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis
    Fujimoto, Daichi
    Ueda, Hiroyuki
    Shimizu, Ryoko
    Kato, Ryoji
    Otoshi, Takehiro
    Kawamura, Takahisa
    Tamai, Koji
    Shibata, Yumi
    Matsumoto, Takeshi
    Nagata, Kazuma
    Otsuka, Kyoko
    Nakagawa, Atsushi
    Otsuka, Kojiro
    Katakami, Nobuyuki
    Tomii, Keisuke
    CLINICAL & EXPERIMENTAL METASTASIS, 2014, 31 (05) : 543 - 551
  • [24] TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC
    Soo, R.
    De Marinis, F.
    Han, J. -Y.
    Ho, C. M. J.
    Lin, Y.
    Servidio, L.
    Sandelin, M.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S272 - S272
  • [25] Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)
    Fukuhara, T.
    Inoue, A.
    Morita, S.
    Sugawara, S.
    Hosomi, Y.
    Ikeda, S.
    Gemma, A.
    Takahashi, K.
    Fujita, Y.
    Harada, T.
    Minato, K.
    Takamura, K.
    Kobayashi, K.
    Nukiwa, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S467 - S467
  • [26] A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia
    DeAngelo, Daniel J.
    Neuberg, Donna
    Amrein, Philip C.
    Berchuck, Jacob
    Wadleigh, Martha
    Sirulnik, L. Andres
    Galinsky, Ilene
    Golub, Todd
    Stegmaier, Kimberly
    Stone, Richard M.
    LEUKEMIA RESEARCH, 2014, 38 (04) : 430 - 434
  • [27] FINAL REPORT OF A PHASE I STUDY OF CONCURRENT THORACIC RADIOTHERAPY AND GEFITINIB IN PRE-TREATED PATIENTS WITH IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)
    Shen, Yu-Xin
    Fan, Min
    Chen, Jia-Yan
    Xie, Li-Yi
    Xu, Xuan-Li
    Zhang, Guo-Q
    Fu, Xiao-Long
    Jiang, Guo-Liang
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1584 - S1584
  • [28] A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage IIIB-IV Non-small Cell Lung Cancer
    Akerley, Wallace
    Boucher, Kenneth M.
    Bentz, Joel S.
    Arbogast, Kylee
    Walters, Theodore
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (02) : 214 - 219
  • [29] First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies
    Morikawa, Naoto
    Minegishi, Yuji
    Inoue, Akira
    Maemondo, Makoto
    Kobayashi, Kunihiko
    Sugawara, Shunichi
    Harada, Masao
    Hagiwara, Koichi
    Okinaga, Shoji
    Oizumi, Satoshi
    Nukiwa, Toshihiro
    Gemma, Akihiko
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 465 - 472
  • [30] Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations
    Uchibori, Ken
    Satouchi, Miyako
    Sueoka-Aragane, Naoko
    Urata, Yoshiko
    Sato, Akemi
    Imamura, Fumio
    Inoue, Takako
    Tachihara, Motoko
    Kobayashi, Kazuyuki
    Katakami, Nobuyuki
    Kokan, Chiyuki
    Hirashima, Tomonori
    Iwanaga, Kentaro
    Mori, Masahide
    Aoe, Keisuke
    Morita, Satoshi
    Negoro, Shunichi
    LUNG CANCER, 2018, 124 : 65 - 70
12345